NO20033910L - Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin - Google Patents

Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin

Info

Publication number
NO20033910L
NO20033910L NO20033910A NO20033910A NO20033910L NO 20033910 L NO20033910 L NO 20033910L NO 20033910 A NO20033910 A NO 20033910A NO 20033910 A NO20033910 A NO 20033910A NO 20033910 L NO20033910 L NO 20033910L
Authority
NO
Norway
Prior art keywords
tegafur
carboplatin
paclitaxel
uracil
tumors
Prior art date
Application number
NO20033910A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033910D0 (no
Inventor
Jafferhusen A Ajani
Steven E Benner
Terry S Dugan
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO20033910D0 publication Critical patent/NO20033910D0/no
Publication of NO20033910L publication Critical patent/NO20033910L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20033910A 2001-03-06 2003-09-04 Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin NO20033910L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27357701P 2001-03-06 2001-03-06
PCT/US2002/006262 WO2002076459A1 (en) 2001-03-06 2002-03-04 Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin

Publications (2)

Publication Number Publication Date
NO20033910D0 NO20033910D0 (no) 2003-09-04
NO20033910L true NO20033910L (no) 2003-10-23

Family

ID=23044526

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033910A NO20033910L (no) 2001-03-06 2003-09-04 Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin

Country Status (20)

Country Link
US (1) US6770653B2 (cg-RX-API-DMAC7.html)
EP (1) EP1368034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005506294A (cg-RX-API-DMAC7.html)
KR (1) KR20030081496A (cg-RX-API-DMAC7.html)
BR (1) BR0207443A (cg-RX-API-DMAC7.html)
CA (1) CA2439676A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ20032266A3 (cg-RX-API-DMAC7.html)
EE (1) EE200300429A (cg-RX-API-DMAC7.html)
HR (1) HRP20030801A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0303466A3 (cg-RX-API-DMAC7.html)
IL (1) IL157357A0 (cg-RX-API-DMAC7.html)
IS (1) IS6925A (cg-RX-API-DMAC7.html)
MX (1) MXPA03007989A (cg-RX-API-DMAC7.html)
NO (1) NO20033910L (cg-RX-API-DMAC7.html)
PL (1) PL363967A1 (cg-RX-API-DMAC7.html)
RU (1) RU2284184C2 (cg-RX-API-DMAC7.html)
SK (1) SK10602003A3 (cg-RX-API-DMAC7.html)
WO (1) WO2002076459A1 (cg-RX-API-DMAC7.html)
YU (1) YU69903A (cg-RX-API-DMAC7.html)
ZA (1) ZA200306541B (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
CN1761665A (zh) 2003-03-14 2006-04-19 大鹏药品工业株式会社 抗肿瘤效果增强剂和抗肿瘤剂
WO2004087105A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination formulations of platinum agents and fluoropyrimidines
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008202078B2 (en) * 2007-10-10 2012-05-31 Wellkey Holdings Limited Stability of secondary metabolite mass production through synchronized plant cell cultures
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
US20180085377A1 (en) * 2015-04-22 2018-03-29 Syn-Nat Products Enterprise LLC Co-crystal composition and its pharmaceutical use
IL265044B2 (en) 2016-08-31 2025-02-01 Fujifilm Corp An antitumor preparation containing the substances nab-paclitaxel and 1-(2-deoxy-2-fluoro-4-thio-D-beta-arabinofurnosyl)cytosine, a kit containing these substances and their uses
RU2646450C1 (ru) * 2017-05-11 2018-03-05 Владимир Михайлович Курусин Способ лечения предраковых и ранних стадий раковых заболеваний желудка
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
US4328229A (en) 1978-03-29 1982-05-04 Taiho Pharmaceutical Company Limited Anti-cancer composition for delivering 5-fluorouracil to cancer tissues
US5534513A (en) 1991-09-05 1996-07-09 Taiho Pharmaceutical Company, Ltd. Antitumor potentiator and antitumor composition
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
RU2194541C1 (ru) * 2001-07-13 2002-12-20 Научно-исследовательский институт онкологии Томского научного центра СО РАН Способ комбинированного лечения больных местнораспространенным раком желудка

Also Published As

Publication number Publication date
JP2005506294A (ja) 2005-03-03
EP1368034A1 (en) 2003-12-10
HUP0303466A2 (hu) 2004-01-28
SK10602003A3 (en) 2004-10-05
WO2002076459A1 (en) 2002-10-03
CZ20032266A3 (cs) 2004-02-18
YU69903A (sh) 2006-08-17
ZA200306541B (en) 2004-11-22
RU2284184C2 (ru) 2006-09-27
HUP0303466A3 (en) 2005-02-28
HRP20030801A2 (en) 2004-08-31
RU2003129527A (ru) 2005-03-10
IL157357A0 (en) 2004-02-19
IS6925A (is) 2003-08-22
EE200300429A (et) 2003-12-15
PL363967A1 (en) 2004-11-29
US6770653B2 (en) 2004-08-03
KR20030081496A (ko) 2003-10-17
CA2439676A1 (en) 2002-10-03
BR0207443A (pt) 2004-04-06
NO20033910D0 (no) 2003-09-04
US20020173482A1 (en) 2002-11-21
MXPA03007989A (es) 2003-12-04

Similar Documents

Publication Publication Date Title
NO20033910D0 (no) Fremgangsmåte og doseringsform for behandling av tumorer ved administreringav tegafur, uracil, folinsyre, paclitaxel og karboplatin
WO2002062763A3 (en) Inhibition of raf kinase using quinolyl isoquinolyl or pyridyl ureas
WO2003080582A3 (de) Fredericamycin-derivate
WO2002085857A3 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
WO2005110994A3 (en) Substituted pyrazolyl urea derivatives useful in the treatment of cancer
DE60330895D1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
NO20041277L (no) Farmasoytiske preparater for behandling av astma.
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR0312573A (pt) Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina
DK1200412T3 (da) Antiproliferative imidazolforbindelser
ATE408601T1 (de) Fredericamycin-derivate
DE60215178D1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
NO20040516L (no) Kombinasjonsterapi for behandling av kreft.
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
WO2005105094A3 (en) Cancer treatment method
NO20055307D0 (no) Substituerte isokromanforbindelser for behandling av metabolske forstyrrelser, kreft og andre sykdommer
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
EA200501233A1 (ru) 4-аминопиримидин-5-он
ATE429230T1 (de) Chinazoline derivative und ihre anwendung in der krebsbehandlung
ATE336489T1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
NO20034690D0 (no) Fremgangsmåte for behandling av tumorer ved administrering av tegafur, uracil, folinsyre og cyklofosfamid
NO20076075L (no) 4-anilino-3-kinolinkarbonitriler for behandling av cancer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application